Two relevant urological pathologies in men
Benign prostatic hyperplasia (BPH) is the most common benign tumor in men over 50 years of age and is characterized by an enlargement of this organ. Said enlargement, whose ultimate causes are unknown, entails pressure on the urethra and the neck of the bladder, giving rise to different symptoms in the lower urinary tract.
Among the most common lower urinary tract symptoms (LUTS) are: frequent or urgent need to urinate, interruptions during urination, need to strain during urination, feeling of not completely emptying the bladder, and nocturia or need to urinate frequently at night.
In Spain, the prevalence of BPH is estimated at 11.8% in men over 40 years of age, and can reach 30% in those over 70 years of age. It is the first cause of consultation in the Urology Services and the second cause of admission for surgical intervention in men over 50 years of age.
Erectile dysfunction is defined as the persistent inability to achieve or maintain an erection sufficient for satisfactory sexual intercourse, and originates when the penis does not receive a sufficient amount of blood to allow it to harden and expand in response to sexual arousal. Approximately 40 percent of men over the age of 40 have some degree of erectile dysfunction.
BPH and erectile dysfunction are problems that can occur in the same patient; in fact, several studies have shown that many men with erectile dysfunction also experience BPH symptoms. Thus, in 시알리스 구매 , the prevalence in Spain of erectile dysfunction associated with BPH was evaluated, this being 69.1% before pharmacological treatment. In another study, the prevalence of erectile dysfunction in patients who were candidates for surgery for BPH was 68 percent.
On the other hand, multiple epidemiological investigations have identified a strong association of age with erectile dysfunction and lower urinary tract disorders (LUTS). The severity of LUTS has also been shown to have a significant correlation with the incidence of erectile dysfunction and ejaculatory dysfunction.
The common factor in LUTS and erectile dysfunction lies in the decrease in arterial blood flow and in the irrigation of the organs involved, among other causes.
Mechanism of action of the new drug
Tadalafil (Cialis) 5 milligrams is an inhibitor of the enzyme phosphodiesterase type 5 (PDE5). A predominant expression of this enzyme prevents smooth muscle relaxation, causing decreased blood flow to affected organs.
The drug causes an inhibitory effect on this enzyme, which allows the relaxation of smooth muscle in the penis, bladder and prostate, which increases blood perfusion, improves penile erection and reduces the symptoms of benign prostatic hyperplasia.
"It is the first and only drug approved in the European Union, and now also in Spain, to treat men with erectile dysfunction and signs and symptoms of benign prostatic hyperplasia," says José Antonio Sacristán, medical director of Lilly Spain. "Since many men who have erectile dysfunction also experience signs and symptoms of BPH, having a single drug to treat both pathologies could be an important therapeutic option for both patients and doctors," concludes the specialist.